LXRX News and Press, Lexicon Pharmaceuticals Inc. From 06/20/23

LX9211 is an investigational, non-opioid treatment for diabetic peripheral neuropathic pain INPEFA recently approved for treatment of heart failure THE WOODLANDS, Texas, June 20, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced th...

2023-06-16 05:45:41 ET Coherent: Discounted And Attractive Entry Point For The Medium To Long Term Lexicon Pharmaceuticals Secures Key FDA Approval, But Heavy Lifting Remains Federal Reserve Watch: Markets Are Saying That Other Central Banks Are 'Tighter' Than Th...

2023-06-15 23:02:17 ET Are you on the hunt for the next big thing? Ready to catch the wave before it crests? Then, chances are you’re familiar with penny stocks and looking for the next round of names to add to your watch list. In this article, we’re breaking down some of ...

INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure v...

THE WOODLANDS, Texas, June 06, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies 2023 Global Healthcare Conference, taking place June 7-9, 2023. Lonnel Coats, Lexicon’s chief executive officer, Jeffrey L. Wade, ...

2023-06-06 15:20:52 ET Penny stocks are often characterized by their high volatility. Their low price means that even small price changes can equate to significant percentage gains or losses. For instance, a $0.50 increase on a $1 stock equates to a 50% return. This potential for rapid and ...

2023-06-06 08:37:27 ET Brera Holdings ( BREA ) +104% Acquires Strategic Stake in Manchester United PLC. Hoth Therapeutics ( HOTH ) +24% Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease. GitLab ( GTLB ) +27% Q1 earnings ca...

THE WOODLANDS, Texas, June 05, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the closing of Lexicon’s previously announced public offering and concurrent private placement of shares of its common stock. The closing included the issuance and sale of a...

2023-06-02 09:21:39 ET Shares of small-cap biotech Lexicon Pharmaceuticals (NASDAQ: LXRX) fell by nearly 15% during the first four days of trading this week, according to data provided by S&P Global Market Intelligence . The big loss came after the company announced a $125 m...

2023-06-01 11:28:37 ET Summary Lexicon Pharmaceuticals received FDA approval to market its heart failure drug Inpefa, as well as a broad label compared to rivals like AstraZeneca's Farxiga and Lilly's Jardiance. The company faces significant challenges in marketing Inpefa against ...